Radioiodine Uptake and Thyroid Scintiscanning

Meier, Donald A.; Kaplan, Michael M.

doi:10.1016/s0889-8529(05)70188-2

Cited by 55 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cats with advanced nodular goiter and extensive autonomy, diffuse enlargement is seen, making it difficult to identify the adenomatous nodules on scintiscan. Similar finding are reported in human patients with advanced toxic nodular goiter (Meller et al 2000, Meier & Kaplan 2001, Sarkar 2006, Ianni et al 2013.…”

Section: Thyroid Imagingsupporting

confidence: 89%

ANIMAL MODELS OF DISEASE: Feline hyperthyroidism: an animal model for toxic nodular goiter

Peterson¹

2014

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Thyroid Imagingsupporting

confidence: 89%

ANIMAL MODELS OF DISEASE: Feline hyperthyroidism: an animal model for toxic nodular goiter

Peterson¹

2014

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…The diagnostic specificity is further decreased in small lesions (<1 cm) that are below the resolution threshold of scintigraphy (100,106,107).…”

Section: Diagnostic Accuracymentioning

confidence: 99%

American Association Of Clinical Endocrinologists, Associazione Medici Endocrinologi, And European Thyroid Association Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules

Gharib¹,

Papini²,

Paschke³

et al. 2010

Endocrine Practice

832

819

View full text Add to dashboard Cite

“…The scan was done after 24hours using a linear collimator to confirm the presence of diffuse goiter [10]. FT3 and FT4 were estimated by the electrochemiluminescence (ECL) technique using commercially available kits from Roche Diagnostics (Mannheim, Germany) with Elecsys 1010 analyzer.…”

Section: Investigation Methodsmentioning

confidence: 99%

Predictive value of common clinical and laboratory parameters in predicting response to Anti thyroid drug therapy in Graves� Hyperthyroidism � A prospective study

Gopalakrishnan

Chugh

Chhillar

et al. 2013

IJM

View full text Add to dashboard Cite

Purpose: Graves' hyperthyroidism (GH) is commonly treated by antithyroid drugs (ATD). This study was undertaken to identify those clinical factors that could predict sustained remission with ATD so as to avoid unwanted therapy. Approach: Subjects (n=134) diagnosed with GH were consecutively recruited. Carbimazole was administered for 18 months as per titration regimen and subsequently followed up for upto 1 month to detect relapse of thyrotoxicosis. Results: In final analysis of 115 subjects, 61 remained in remission while thyrotoxicosis recurred in 54 subjects during follow-up. Parameters associated with remission for at least 6 months were: smaller goiter, lower free triiodothyronine (FT3) values at onset and euthyroidism in response to ATD within 3 -6 months. Conclusions: 50% of patients went into remission with carbimazole therapy for 18 months. Subjects who fail to achieve euthyroidism with 6 months of ATD should be offered radioiodine or surgery.

show abstract

Radioiodine Uptake and Thyroid Scintiscanning

Cited by 55 publications

References 23 publications

ANIMAL MODELS OF DISEASE: Feline hyperthyroidism: an animal model for toxic nodular goiter

ANIMAL MODELS OF DISEASE: Feline hyperthyroidism: an animal model for toxic nodular goiter

American Association Of Clinical Endocrinologists, Associazione Medici Endocrinologi, And European Thyroid Association Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules

Predictive value of common clinical and laboratory parameters in predicting response to Anti thyroid drug therapy in Graves� Hyperthyroidism � A prospective study

Contact Info

Product

Resources

About